Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.12, marking a +1.43% move from the previous day. The stock’s change was more than the S&P 500’s daily loss of 0.1%. Elsewhere, the Dow saw an upswing of 0.35%, while the tech-heavy Nasdaq depreciated by 0.43%.
The drugmaker’s stock has climbed by 7.45% in the past month, exceeding the Medical sector’s gain of 1.97% and the S&P 500’s loss of 1.34%.
Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. On that day, Vertex Pharmaceuticals is projected to report earnings of $4.79 per share, which would represent year-over-year growth of 5.97%. At the same time, our most recent consensus estimate is projecting a revenue of $3.22 billion, reflecting a 8.46% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $19.15 per share and a revenue of $13.03 billion, signifying shifts of +4.08% and +8.57%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Vertex Pharmaceuticals. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we’ve established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.12% higher. Right now, Vertex Pharmaceuticals possesses a Zacks Rank of #3 (Hold).
Investors should also note Vertex Pharmaceuticals’s current valuation metrics, including its Forward P/E ratio of 24.47. For comparison, its industry has an average Forward P/E of 21.67, which means Vertex Pharmaceuticals is trading at a premium to the group.
It’s also important to note that VRTX currently trades at a PEG ratio of 1.78. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company’s projected earnings growth. As the market closed yesterday, the Medical – Biomedical and Genetics industry was having an average PEG ratio of 1.52.
